Pharmacokinetics and Safety in Rhesus Monkeys of a Monoclonal Antibody-GDNF Fusion Protein for Targeted Blood-Brain Barrier Delivery

@article{Pardridge2009PharmacokineticsAS,
  title={Pharmacokinetics and Safety in Rhesus Monkeys of a Monoclonal Antibody-GDNF Fusion Protein for Targeted Blood-Brain Barrier Delivery},
  author={William M Pardridge and Ruben J. Boado},
  journal={Pharmaceutical Research},
  year={2009},
  volume={26},
  pages={2227 - 2236}
}
Glial-derived neurotrophic factor (GDNF) is a potential therapy for stroke, Parkinson’s disease, or drug addiction. However, GDNF does not cross the blood-brain barrier (BBB). GDNF is re-engineered as a fusion protein with a chimeric monoclonal antibody (MAb) to the human insulin receptor (HIR), which acts as a molecular Trojan horse to deliver the GDNF across the BBB. The pharmacokinetics (PK), toxicology, and safety pharmacology of the HIRMAb-GDNF fusion protein were investigated in Rhesus… CONTINUE READING
12 Extracted Citations
37 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 12 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 37 references

Time-course of GDNF and its receptor expression after brain injury in the rat

  • Q Cheng, V DiLiberto, G Caniglia, M. Giuseppa
  • Neurosci Lett
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…